Eureka Therapeutics Announces New GPRC5D License Agreement with Sanofi to Target Multiple Myeloma
The GPRC5D binding domain was discovered using Eurekas proprietary E-ALPHA antibody discovery platform and developed under a collaboration agreement between Eureka and MSK.
- The GPRC5D binding domain was discovered using Eurekas proprietary E-ALPHA antibody discovery platform and developed under a collaboration agreement between Eureka and MSK.
- GPRC5D is a novel target that has emerged as a promising option for the treatment of multiple myeloma, particularly for patients who have relapsed from other therapies, said Dr. Eric L. Smith, myeloma physician-scientist and an inventor on the patents.
- We are delighted to contribute technology for the development of next generation therapies against multiple myeloma, said Dr. Cheng Liu, President and Chief Executive Officer of Eureka Therapeutics.
- Under the terms of the agreement, Sanofi has exclusive rights to the GPRC5D binder for non-CAR use.